Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491755 | 0.80 | AKR1C3 (0.47) | CYP2C19CYP2D6SRCLMNAMTNR1A | |
| SCHEMBL4423829 | 0.76 | CYP2C19 (0.42) | CYP2C19LMNA | |
| SCHEMBL6053632 | 0.74 | LMNA (0.41) | CYP2C19CYP2D6SRCLMNAHTR2A | |
| SCHEMBL10991394 | 0.72 | HTR2A (0.40) | CYP2C19CYP2D6LMNAMAPK1HTR2A | |
| SCHEMBL3144362 | 0.71 | HCAR2 (0.44) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL7238650 | 0.71 | HCAR2 (0.44) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL8669010 | 0.71 | CYP2C19 (0.44) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL7239259 | 0.71 | HCAR2 (0.44) | CYP2C19CYP2D6SRCLMNAMAPK1 | |
| SCHEMBL68782 | 0.70 | HTR2A (0.46) | CYP2C19CYP2D6SRCHTR2ATAAR1 | |
| SCHEMBL5381347 | 0.70 | CYP2D6 (0.44) | CYP2C19CYP2D6SRCLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432386-B2 | Diarylbutadiene-substituted methyltrialkylsilanes and photoprotective compositions comprised thereof | L'OREAL (FR) | 2008-10-07 | — | — | US | disclosed |
| US-20070213547-A1 | For UV-photoprotecting human skin against the damaging effects of UV-radiation, notably UV-A radiation; example: monotrimethylsilanylmethyl monoethyl diester of (3,3-diphenyl-2-propylidene)propanedioic acid; good resistance to water and to perspiration | L'OREAL | 2007-09-13 | — | — | US | disclosed |
| US-7229609-B2 | Diarylbutadiene-substituted methyltrialkylsilanes and photoprotective compositions comprised thereof | L'OREAL (FR) | 2007-06-12 | — | — | US | disclosed |
| US-20050201957-A1 | Diarylbutadiene-substituted methyltrialkylsilanes and photoprotective compositions comprised thereof | L'OREAL (FR) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213547-A1 | For UV-photoprotecting human skin against the damaging effects of UV-radiation, notably UV-A radiation; example: monotrimethylsilanylmethyl monoethyl diester of (3,3-diphenyl-2-propylidene)propanedioic acid; good resistance to water and to perspiration | CUTA, DDB1, DCLRE1A | CYP2C19 1207/4885CYP2D6 602/4885SRC 4203/4885 |
| US-20050201957-A1 | Diarylbutadiene-substituted methyltrialkylsilanes and photoprotective compositions comprised thereof | MGMT, DDB1, ERCC1 | CYP2C19 559/4885CYP2D6 806/4885SRC 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.